Axsome Therapeutics Inc annual free cash flow for fiscal TTM was -$72 million, an increase of 23.4% from -$94 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($72M) | ($94M) | ($129M) | ($146M) | ($117M) | ($109M) | ($79M) | ($46M) | ($30M) | ($26M) | ($21M) | ($7M) | ($5M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | ($33M) | ($21M) | ($19M) | $1M | ($32M) | ($44M) | ($26M) | ($19M) | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AXSM metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All AXSM financial statements → Interactive AXSM charts →
About TickerBase · Data methodology & sources · Privacy · Terms